Survival of children with neuroblastoma: time trends and regional differences in Europe, 1978-1992

被引:41
作者
Spix, C [1 ]
Aareleid, T
Stiller, C
Magnani, C
Kaatsch, P
Michaelis, J
机构
[1] Johannes Gutenberg Univ Mainz, Deutsch Kinderkrebsregister, IMSD, D-55101 Mainz, Germany
[2] Inst Expt & Clin Med, Dept Epidemiol & Biostat, Tallinn, Estonia
[3] Estonian Canc Ctr, Estonian Canc Registry, Tallinn, Estonia
[4] Childhood Canc Res Grp, Natl Registry Childhood Tumours, Oxford, England
[5] Childhood Canc Registry Piedmont, Reg Ctr Canc Epidemiol & Prevent Piedmont, Turin, Italy
关键词
neuroblastoma; survival rates; time trends in survival; Europe;
D O I
10.1016/S0959-8049(01)00003-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neuroblastoma is one of the most common solid cancers in children. We present the data collected for the EUROCARE II study, describing survival patterns for children diagnosed in Europe 1985-1989 in detail: and exploring time trends from 1978 to 1992. On average, the mean 5-year survival rate was considerably higher in infants (79%) compared with older children (30-33%). The risk of death has dropped by 37% from 1978-1981 to 1990-1992. There is a pronounced difference between countries, with Scotland and England and Wales having two of the lowest survival rates (28% (95% confidence interval (CI) 14048) and 36% (95% CI 31-41) 5-year survival rates, respectively). The survival rates in France, Germany and Italy (48-66% 5-year survival rate) were among the highest. This pattern corresponds to the incidence rates for these countries. It can be assumed that in neuroblastoma, both incidence and survival are related to the frequency of diagnosing asymptomatic cases with good prognosis among infants. However, one cannot ignore possible intercountry differences in the effectiveness of therapy. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:722 / 729
页数:8
相关论文
共 34 条
[1]   Effects of mass screening for neuroblastoma on incidence, mortality, and survival rates in Osaka, Japan [J].
Ajiki, W ;
Tsukuma, H ;
Oshima, A ;
Kawa, K .
CANCER CAUSES & CONTROL, 1998, 9 (06) :631-636
[2]  
[Anonymous], 1995, IARC SCI PUBLICATION
[3]   Introduction: The EUROCARE II study [J].
Berrino, F ;
Gatta, G ;
Chessa, E ;
Valente, F ;
Capocaccia, R .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (14) :2139-2153
[4]   The current contributional of molecular factors to risk estimation in neuroblastoma patients [J].
Berthold, F ;
Sahin, K ;
Hero, B ;
Christiansen, H ;
Gehring, M ;
Harms, D ;
Horz, S ;
Lampert, F ;
Schwab, M ;
Terpe, J .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (12) :2092-2097
[5]  
Berthold F, 1996, ANN ONCOL, V7, P183
[6]  
Brodeur GM, 1998, MED PEDIATR ONCOL, V31, P394
[7]  
Brossard J, 1996, BRIT MED BULL, V52, P787
[8]   Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992 [J].
Cotterill, SJ ;
Pearson, ADJ ;
Pritchard, J ;
Foot, ABM ;
Roald, B ;
Kohler, JA ;
Imeson, J .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (07) :901-908
[9]   CHILDHOOD-CANCER - TRENDS IN INCIDENCE, SURVIVAL AND MORTALITY [J].
DRAPER, GJ .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (05) :653-654
[10]  
Goodman MT, 1999, CANC INCIDENCE SURVI, P65